Clinical trial
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and…
NCT00287287 · Kenneth Ain, Other · Completed
Key facts
| NCT number | NCT00287287 |
|---|---|
| Title | REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas |
| Official title | Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas |
| Lead sponsor | Kenneth Ain, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Neoplasms |
| Intervention type | Drug |
| Interventions | Lenalidomide |
| Enrollment | 25 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 6, 2010 |
| Completion | Jul 6, 2010 |
| First posted | Feb 6, 2006 |
| Last update posted | Jun 12, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: